NDA 017442 · Pfizer
Minipress
Prazosin Hydrochloride · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jan 8, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1976
Jun 23, 1976
Approved uses
1
Original approval plus efficacy supplements
Registered trials
114
9 Phase 3, 2 recruiting
FAERS reports
1,387
873 serious, 91 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 5, 2026.
INDICATIONS AND USAGE Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 23, 1976 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
- MINIPRESS · PRAZOSIN HYDROCHLORIDE EQ 2MG BASE · CAPSULE, ORAL · Prescription · TE AB
- MINIPRESS · PRAZOSIN HYDROCHLORIDE EQ 5MG BASE · CAPSULE, ORAL · Prescription · TE AB
- MINIPRESS · PRAZOSIN HYDROCHLORIDE EQ 1MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Prazosin" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Medical Therapy of Prostatic SymptomsPivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00021814 · 3,407 participants · Start Dec 1995 · Primary completion Nov 30, 2001
Drug: Doxazosin; Finasteride and 2 more · For: Prostatic Hyperplasia; Prostatic Hypertrophy, Benign
Sites: La Jolla, California; Aurora, Colorado; New Haven, Connecticut · 17 sites in all
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of ChronotherapyPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00295542 · 3,344 participants · Start Mar 2000 · Primary completion Apr 2009
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) and 2 more · For: Hypertension
Sites: Santiago de Compostela, Spain
- Nephropathy In Type 2 Diabetes and Cardio-renal EventsPivotal-lookingCompleted
University of Campania Luigi VanvitelliAcademic, hospital or other
NCT00535925 · 850 participants · Start Oct 2005 · Primary completion Dec 2011
Drug: SoC therapy; irbesartan and 12 more · For: Diabetic Nephropathy
Sites: Naples, Italy
- A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and ComorbidityPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02655354 · 635 participants · Start Oct 2015 · Primary completion Nov 2019
Drug: Fluoxetine; Fluvoxamine and 9 more · For: Posttraumatic Stress Disorder; Depression; Alcohol-Related Disorders and 8 more
Sites: Scottsdale, Arizona; Beverly Hills, California; Sacramento, California · 24 sites in all
- Japan Morning Surge-1 StudyPivotal-lookingCompleted
Japan Heart FoundationAcademic, hospital or other
NCT00285519 · 600 participants · Start Aug 2003
Drug: Doxazosin (drug) · For: Hypertension
Sites: Shimotsuke, Japan
- Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1Pivotal-lookingCompleted
Buddhist Tzu Chi General HospitalAcademic, hospital or other
NCT01661621 · 395 participants · Start Aug 2012 · Primary completion Aug 2013
Drug: Detrusitol 4 mg QD; Doxazosin 4 mg QD · For: Bladder Outlet Obstruction
Sites: Hualien City, Taiwan
- Optimum Treatment for Drug-Resistant HypertensionPivotal-lookingStatus unknown
University of CambridgeAcademic, hospital or other
NCT02369081 · 348 participants · Start May 2009 · Primary completion Jul 2015
Drug: Spironolactone; Bisoprolol and 2 more · For: Hypertension, Resistant to Conventional Therapy
Sites: Ayrshire, United Kingdom; Birmingham, United Kingdom; Cambridge, United Kingdom · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue115
- off label use106
- abdominal pain105
- product dose omission issue104
- drug ineffective91
- nausea89
- diarrhoea75
- pain74
- renal impairment72
- heart failure with preserved ejection fraction69
- headache67
- dyspnoea63
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 9 |
| 2006 | 6 |
| 2008 | 4 |
| 2009 | 15 |
| 2010 | 22 |
| 2011 | 12 |
| 2012 | 21 |
| 2013 | 18 |
| 2014 | 12 |
| 2015 | 14 |
| 2016 | 16 |
| 2017 | 22 |
| 2018 | 17 |
| 2019 | 32 |
| 2020 | 47 |
| 2021 | 65 |
| 2022 | 177 |
| 2023 | 144 |
| 2024 | 244 |
| 2025 | 298 |
| 2026 | 183 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials.
Skeie-Larsen M, Stave R, Grønli J, et al. · Int J Environ Res Public Health 2022 · Systematic Review, Meta-Analysis
- Raynaud's phenomenon (primary).
Pope JE · BMJ Clin Evid 2011 · Systematic Review
- The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.
Chen A, Copeli F, Metzger E, et al. · Psychiatry Res 2021 · Meta-Analysis, Systematic Review
- Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis.
Huang CY, Zhao YF, Zhang ZX, et al. · Ann Med 2024 · Systematic Review, Network Meta-Analysis
- Understanding the current evidence base for the commonly recommended management strategies for recurrent feline idiopathic cystitis: a systematic review.
Macleod B, Laven LJ, Laven RA, et al. · N Z Vet J 2025 · Systematic Review
- Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches.
Hoskins MD, Bridges J, Sinnerton R, et al. · Eur J Psychotraumatol 2021 · Meta-Analysis, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.